Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Altitude Life Science Ventures
AddedFeb 13, 2024
UpdatedJun 28, 2026
Altitude Life Science Ventures

Altitude Life Science Ventures

Operating

Altitude Life Science Ventures: Investing in early-stage life science firms with high growth potential.

Location
Kirkland, WA, US
Founded
2005
Firm
Compare
Portfolio
Employees
Website

Investments

Ring Therapeutics
Ring Therapeutics

Total Raised

$253.5M

Rounds

3

Series C$86.5MMarch 2023
Series B$117MJuly 2021
Escient Pharmaceuticals
Escient Pharmaceuticals
Public

Total Raised

$237.5M

Rounds

3

Series C$120MNovember 2022
Ansa Biotechnologies
Ansa Biotechnologies

Total Raised

$83.4M

Rounds

6

Series A$68MApril 2022
Generate Biomedicines
Generate Biomedicines

Total Raised

$693M

Rounds

3

Series B$370MNovember 2021
Mozart Therapeutics
Mozart Therapeutics

Total Raised

$80M

Rounds

2

Series A$55MOctober 2021
CERo Therapeutics
CERo Therapeutics

Total Raised

$41.4M

Rounds

2

Series A$40MMarch 2020
Encoded Therapeutics
Encoded Therapeutics

Total Raised

$239.1M

Rounds

3

Series C$104MJune 2019
BlackThorn Therapeutics
BlackThorn Therapeutics
Acquired

Total Raised

$138M

Rounds

4

Series B$76MJune 2019
Series A$40MOctober 2016
Vividion Therapeutics
Vividion Therapeutics
Acquired

Total Raised

$371.5M

Rounds

5

Series B$82MApril 2019
Beam Therapeutics
Beam Therapeutics
Public

Total Raised

$689M

Rounds

5

Series B$135MMarch 2019
Unity Biotechnology
Unity Biotechnology
Public

Total Raised

$294.9M

Rounds

9

Series C$55MMarch 2018
Vir Biotechnology
Vir Biotechnology
Public

Total Raised

$908.6M

Rounds

9

Series Unknown$150MJanuary 2017
Pulmatrix
Pulmatrix
Public

Total Raised

$148.4M

Rounds

11

Post Ipo Equity$10MJune 2015
Siluria Technologies
Siluria Technologies

Total Raised

$150.7M

Rounds

7

Series C$30MJuly 2012
Series B$20MSeptember 2011
Series A$13.3MOctober 2010
Cambrios Technologies
Cambrios Technologies

Total Raised

$81.1M

Rounds

9

Series D$14.5MNovember 2009
Limerick BioPharma
Limerick BioPharma

Total Raised

$47.1M

Rounds

6

Series C$15MJuly 2009
Series Unknown$15.2MJune 2008
Arete Therapeutics
Arete Therapeutics
Public

Total Raised

$51.7M

Rounds

2

Series A$16.7MNovember 2008
Series A$35MMay 2007